ZEJULA (niraparib) is an orally available poly(ADP-ribose) polymerase (PARP) inhibitor. Each ZEJULA capsule contains 159.4 mg niraparib tosylate monohydrate equivalent to 100 mg niraparib free base as the active ingredient. The inactive ingredients in the capsule fill are magnesium stearate and lactose monohydrate.Niraparib tosylate monohydrate is a white to off-white, non-hygroscopic crystalline solid.
ZEJULA (niraparib) Capsules: 100 mg
Recommended dosage is 300 mg taken once daily with or without food. *Continue treatment until disease progression or unacceptable adverse reaction. * For adverse reactions, consider interruption of treatment, dose reduction, or dose discontinuation.
ZEJULA (niraparib) is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.